CytoMed Therapeutics Limited (GDTC)

CytoMed Therapeutics Limited at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

CytoMed Therapeutics Limited (GDTC) is a Biotechnology company based in SG with a market capitalization of $11.5M. Revenue grew 513.8% year-over-year and free cash flow was negative at -$4.4M. This page tracks GDTC's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

SG · 43 employees · IPO Apr 14, 2023

Valuation

Valuation & price

$1.16as of May 26, 2026· -56.9% vs 52w high

P/E ratio

Latest-FY diluted EPS

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$2.57$1.65$0.72Jul 25Jan 26Jul 26
$0.7252-week range$2.69
Loading valuation history…

Fundamentals

Key fundamentals

$11.5M

Market cap

513.8%

Revenue growth (YoY)

-277.7%

Gross margin

-$4.4M

Free cash flow (USD)

-$1.6M

Net debt

Net cash position

0.9%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20192025

$0$319.2K

Free cash flow by year

20192025

-$1.3M-$4.4M

Gross margin by year

20212025

96.9%-277.7%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

3

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last reported: Jun 30, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider buyJul 24, 2026Filing

    Insider Buy $300KChoo Chee Kong · Director, 10% Owner · $300K

  • Insider buyJul 24, 2026Filing

    Insider Buy $300KChoo Chee Kong · Director, 10% Owner · $300K

  • 6-K filingJun 23, 2026Filing

    Share Purchase Agreement

  • Insider buyJun 15, 2026Filing

    Insider Buy $129KChoo Chee Kong · Director, 10% Owner · $128.8K

  • Annual reportJun 3, 2026Filing

    Annual Report Filed

  • 6-K filingMay 15, 2026Filing

    Management Change

  • 6-K filingMay 11, 2026Filing

    Name Change Announcement

  • Annual reportApr 14, 2026Filing

    Annual Report Filed

Questions

Frequently asked questions

What is CytoMed Therapeutics Limited's market cap?

CytoMed Therapeutics Limited (GDTC) has a market capitalization of $11.5M.

What is GDTC's P/E ratio?

A meaningful P/E ratio is not available for GDTC — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

When did CytoMed Therapeutics Limited last report earnings?

GDTC last reported earnings on June 30, 2026; the next date is not yet scheduled.

Are insiders buying GDTC stock?

Yes — SEC Form 4 filings show 3 open-market insider buys and 0 sells at CytoMed Therapeutics Limited in the last 90 days.

Same arena

Related companies in Biotechnology

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.